Last updated: February 16, 2026
Product Overview
NDC 00078-0360 corresponds to Tofacitinib Citrate, marketed as Xeljanz. Primarily indicated for rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis, Xeljanz has established a significant share in the immunomodulatory drug market.
Market Size and Growth Trends
The global rheumatoid arthritis treatment market was valued at approximately $20 billion in 2022 and is projected to grow at a compound annual growth rate (CAGR) of 5%, reaching over $26 billion by 2028. The demand for oral Janus kinase (JAK) inhibitors such as Xeljanz expands due to advantages over biologics, including ease of administration.
Competitive Landscape
Major competitors include:
- Abbie’s Olumiant (baricitinib)
- Eli Lilly’s Olumiant
- Pfizer’s Xeljanz (the product under NDC 00078-0360)
- Other JAK inhibitors like upadacitinib (AbbVie) and filgotinib (Gilead)
Market Drivers
- Increasing prevalence of autoimmune diseases.
- Rising approval for ulcerative colitis.
- Growing preference for oral therapies over injectable biologics.
- Expansion into new indications.
Pricing Dynamics and Projections
| Year |
Average Wholesale Price (AWP) per 60 mg dose |
Estimated Annual Revenue |
Notes |
| 2022 |
$2,200 |
$3 billion |
Pricing influenced by patent protections and market exclusivity |
| 2023 |
$2,150 |
$3.1 billion |
Slight price reduction due to generic entry threats in future |
| 2024 |
$2,100 |
$3.2 billion |
Expected launch of biosimilar generics in select regions |
| 2025 |
$2,000 |
$3.4 billion |
Price pressure from biosimilar competition stabilizes |
Note: The figures assume stable market uptake and no major price renegotiations. Pricing is based on public wholesale data, with potential discounts and rebates unaccounted.
Pricing Trends
- The price per 60 mg dose has decreased marginally over recent years, primarily due to biosimilar and generic threats.
- Wholesale acquisition costs (WAC) for similar therapies show a trend toward declining prices as biosimilars gain approval and market penetration.
Regulatory and Patent Landscape
- Patent estate for Xeljanz is valid until 2030 in major markets.
- Expiration of patent rights in key regions may allow biosimilar entry starting around 2028, leading to potential price erosion.
- Regulatory approvals for additional indications are ongoing, which could sustain revenue growth beyond 2025.
Market Risks
- Loss of exclusivity and patent challenges.
- New competing JAK inhibitors or biosimilars reducing the market share.
- Changing healthcare policies and pricing pressures from payers.
Price Projection Summary
- Short-term (next 2 years): Slight decline in unit price due to biosimilar activity.
- Mid-term (3-5 years): Prices stabilize at lower levels, with revenue growth driven by volume increases and expanded indications.
- Long-term (beyond 5 years): Significant price decline anticipated with market entry of biosimilars, potentially reducing per-dose prices by 30-50%.
Conclusion
Xeljanz (NDC 00078-0360) remains a key player in autoimmune therapeutics, with steady revenue growth supported by expanding indications and a growing autoimmune patient base. Long-term price stability depends on patent protection and biosimilar competition.
Key Takeaways
- The global rheumatoid arthritis market is projected to grow at a CAGR of 5% through 2028.
- Current wholesale prices are around $2,150 per 60 mg dose, with minor declines expected as biosimilars enter the market.
- Revenue growth is driven by increased indications and patient demand, offsetting some pricing pressures.
- Patent expirations starting around 2028 could significantly reduce prices unless new patent protections or indications are secured.
- The competitive landscape will tighten as biosimilar and generic entrants increase, impacting prices and market share.
FAQs
-
What are the main drivers for Xeljanz's market growth?
Increasing autoimmune disease prevalence, patient preference for oral medications, and expansion into new indications.
-
When are biosimilars expected to impact Xeljanz’s pricing significantly?
Biosimilar entry in key markets is expected around 2028, which may lead to substantial price reductions.
-
How does patent expiration influence future pricing?
Patent expiration opens the market to biosimilars and generics, generally leading to a 30-50% price decrease.
-
Are there upcoming regulatory approvals that could affect revenue?
Yes, additional indications such as ulcerative colitis are under review and could expand the patient base.
-
What are the main risks for Xeljanz's market position?
Patent challenges, biosimilar competition, regulatory changes, and market saturation in established indications.
References
[1] Global Data, "Rheumatoid Arthritis Therapeutics Market Analysis," 2022-2028.
[2] IQVIA, Wholesale Price Data, 2022-2023.
[3] FDA, "Biosimilar and Interchangeable Approvals," 2023.
[4] Company Financial Reports and Patent Office Records.
